iNOS, COX-2 and HIF-1α may act synergistically, and inhibition of iNOS may reduce both COX-2 and HIF-1α expression in tumours, enhancing the efficacy of cancer therapy [7,17,64,67]. The gene discussed is HIF1A; the disease is cancer.